Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
Holding GMED?
Track your performance easily
GMED Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$43.39 - $75.98
Previous Close$72.85
Volume606.21K
Average Volume (3M)818.76K
Market Cap
$9.86B
Enterprise Value$10.31B
Total Cash (Recent Filing)$82.51M
Total Debt (Recent Filing)$529.30M
Price to Earnings (P/E)246.0
Beta1.25
Next Earnings
Nov 05, 2024EPS Estimate
$0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.30
Shares Outstanding135,407,017
10 Day Avg. Volume828,227
30 Day Avg. Volume818,760
Standard Deviation0.10
R-Squared0.37
Alpha-0.00402
Financial Highlights & Ratios
Price to Book (P/B)2.48
Price to Sales (P/S)4.41
Price to Cash Flow (P/CF)45.50
P/FCF Ratio88.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.61
Enterprise Value/Gross Profit10.11
Enterprise Value/Ebitda23.93
Forecast
1Y Price Target
$79.58Price Target Upside8.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Globus Medical News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTotal sales were $630 million, reflecting a 116% year-over-year increase and surpassing market expectations by approximately 2%.
Product DevelopmentGMED launched four new products in 2Q24, with a year-to-date total of nine introductions, setting expectations for a record number of launches this year.
Robotic SystemsThe company experienced its highest number of robot unit placements in Q2, with a strong pipeline indicating continued growth in this area.
Bears Say
Communication ConcernsThe warning letter came as a surprise to many investors as GMED did not disclose it on its Q2 call despite receiving it weeks earlier.
CompetitionTwo large players recently received FDA approval for their Spine robots, which adds competition for GMED.
Regulatory IssuesIf the company failed to address the FDA’s issues and there were repeat violations during another inspection, then the company would face potentially greater regulatory consequences.
---
Ownership Overview
16.50% Insiders
31.44% Mutual Funds
1.22% Other Institutional Investors
30.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $43.38 and its highest was $75.98 in the past 12 months.
What is Globus Medical’s market cap?
Currently, no data Available
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is Nov 05, 2024 which is in 15 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Aug 06, 2024. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.677 by $0.073.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is $0.65.
How many shares outstanding does Globus Medical have?
Globus Medical has 112,976,920 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $0.75 in its last earnings report, beating expectations of $0.677. Following the earnings report the stock price went up 2.143%.
Which hedge fund is a major shareholder of Globus Medical?
Among the largest hedge funds holding Globus Medical’s share is Fisher Asset Management LLC. It holds Globus Medical’s shares valued at 26M.
---
Globus Medical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$79.58 (8.29% Upside)
$79.58 (8.29% Upside)
Blogger Sentiment
Bullish
GMED Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 247.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.20%
12-Months-Change
Fundamentals
Return on Equity
1.36%
Trailing 12-Months
Asset Growth
125.71%
Trailing 12-Months
Company Description
Globus Medical
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
---
GMED Earnings Call
Q2 2024
0:00 / 0:00
---
GMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
---
GMED Stock 12 Month Forecast
Average Price Target
$79.58
▲(8.29% Upside)
Technical Analysis
Best Analysts Covering GMED
1 Year
1 Year Success Rate
21/28 ratings generated profit
1 Year Average Return
+18.23%
assigned a buy rating 2 months ago
Copying Matt Miksic's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +18.23% per trade.
---